For generations, antibody therapies have patrolled only the outer walls of the cell, unable to reach the hidden machinery where many of the most tenacious diseases are born. A team at Cornell University has now devised a molecular disguise — a cloaking technique using negatively charged ions — that allows these powerful drugs to slip inside cells aboard lipid nanoparticles, arriving where they were never before able to go. Validated independently for both Parkinson's disease and lung inflammation, the approach suggests that the long-standing boundary between extracellular medicine and intracel
Lipid nanoparticles deliver antibodies into cells to fight cancer, inflammation
For the first time, we can take clinically validated antibodies and deliver them to targets inside the cell.
Mark
Why does it matter that antibodies couldn't get inside cells before? Weren't there other ways to treat intracellular diseases?
Mimi
There were workarounds—gene therapy, small molecule drugs—but antibodies are special. They're exquisitely specific. They can be designed to bind one target with almost no off-target effects. If you could get them inside the cell, you'd have a precision tool for diseases that have been hard to reach.
Mark
So the lipid nanoparticles are just delivery trucks?
Mimi
Exactly. But the trick is the cloaking. Without it, the antibody and the nanoparticle repel each other. The negative charge on the cloaked antibody lets it stick electrostatically to the positively charged nanoparticle. Once they're inside the cell, the antibody sheds the cloak and does its job.
Mark
The Israeli team and the Cornell team tested this on completely different diseases. Does that mean it could work for almost anything inside a cell?
Mimi
That's the real question now. What we know is it worked for Parkinson's and lung inflammation. But the principle—cloaking a protein to smuggle it across a membrane—is generalizable. The researchers are already exploring other chemical cloaks beyond sulfonates. The platform could be much broader than any single disease.
Mark
What's the risk? Why isn't this already in patients?
Mimi
It's still early. You need to prove safety and efficacy in humans, not just mice and cell cultures. You need to understand how the body handles these nanoparticles, whether they accumulate anywhere they shouldn't, whether the immune system attacks them. That's the work ahead. But the fact that it worked independently in two different labs is a strong signal.
Mark
Why did they start a company instead of just publishing more papers?
Mimi
Because the science is proven enough now that the next step is translation—getting it into clinical trials, into patients. A company can move faster and attract the capital and expertise needed for that. The researchers are saying, in effect, the platform works. Now let's see what medicine we can build with it.
The Pulse
- Antibody drugs, among medicine's most celebrated tools, have been structurally locked out of the cell interior — where many cancers, neurological disorders, and inflammatory diseases actually originate.
- Cornell engineers cracked the barrier with a 'cloaking' method: coating antibodies in negatively charged sulfonate ions so they can bind to lipid nanoparticles and be carried across the cell membrane like stowaways.
- The urgency of the breakthrough sharpened when Israeli researchers at the Technion independently used the same technique to deliver antibodies into brain cells targeting the Parkinson's-driving protein alpha-synuclein — and it worked.
- A parallel study at MIT confirmed the platform's reach, using cloaked commercial antibodies to reduce lung inflammation in mice, demonstrating that two entirely different diseases yielded to the same delivery system.
- With startup Cloak Bio already launched and researchers exploring additional cloaking chemistries, a platform technology is visibly accelerating from laboratory proof toward clinical application.
For generations, antibody therapies have patrolled only the outer walls of the cell, unable to reach the hidden machinery where many of the most tenacious diseases are born. A team at Cornell University has now devised a molecular disguise — a cloaking technique using negatively charged ions — that allows these powerful drugs to slip inside cells aboard lipid nanoparticles, arriving where they were never before able to go. Validated independently for both Parkinson's disease and lung inflammation, the approach suggests that the long-standing boundary between extracellular medicine and intracellular disease may, at last, be dissolving.
For decades, antibody drugs have been medicine's precision instruments — but only for targets on the outside of cells. The moment a disease driver lives within the cell membrane, antibodies hit an impassable wall: they are simply too large to cross on their own. A Cornell engineering team has now found a way through.
The solution is a molecular disguise. Professors Chris Alabi and Matt DeLisa developed a technique for coating proteins in negatively charged ions, allowing them to electrostatically bind to lipid nanoparticles — tiny fat bubbles that can ferry cargo across the cell membrane. Once inside, the proteins shed their cloaking and go to work. Elegant in theory, the approach needed real-world proof.
That proof arrived from two directions at once. Avi Schroeder's team at the Technion-Israel Institute of Technology had spent years searching for a way to deliver antibodies into brain cells to target alpha-synuclein, the protein implicated in Parkinson's disease. When they learned of the Cornell cloaking compound — a sulfonate group called SL4 — they applied it to their antibodies and achieved exactly what had eluded them. The independent replication, on a different continent under different conditions, was the benchmark that mattered.
Simultaneously, postdoctoral researcher Azmain Alamgir, lead author of a new paper in the Proceedings of the National Academy of Sciences, tested the same platform using commercial antibodies targeting NF-kB, a driver of lung inflammation. In a mouse model of acute lung injury, the cloaked antibodies delivered therapeutic benefit. Two diseases, two tissues, two targets — one delivery system.
The significance runs deeper than the technical feat. Nearly all FDA-approved antibody therapies work on extracellular targets — the accessible surface of the cell. The intracellular landscape, where many of the most compelling disease mechanisms reside, has remained beyond reach. This platform changes that. Alabi and colleagues have already launched Cloak Bio to pursue further applications, and the team is exploring whether other chemical groups beyond sulfonates might extend the cloaking capability still further. In translational science, that is the sound of a new era beginning to move toward the clinic.
For decades, antibody drugs have been among medicine's most effective weapons—but only against targets sitting on the outside of cells. The moment a disease driver lives inside the cell, where many of the most stubborn illnesses actually originate, antibodies hit a wall. They are simply too large to cross the cell membrane on their own. A team of researchers at Cornell has now found a way around that barrier, and the implications are beginning to ripple across multiple diseases.
The solution involves a kind of molecular disguise. In 2024, Chris Alabi and Matt DeLisa, both professors in Cornell's engineering college, published a technique for cloaking proteins by coating them with negatively charged ions. These cloaked proteins can then electrostatically bind to lipid nanoparticles—essentially tiny fat bubbles—which ferry them across the cell membrane. Once inside, the proteins shed their disguise and get to work. The approach was elegant in theory. What came next proved it could work in the real world.
Avi Schroeder's team at the Technion-Israel Institute of Technology had been trying for years to deliver antibodies into brain cells to target alpha-synuclein, a protein that drives Parkinson's disease. When they learned of the Cornell cloaking method, they recognized it as a potential solution. They obtained the cloaking compound—a sulfonate group called SL4—and the protocol for using it, then applied it to their anti-alpha-synuclein antibodies. It worked. The independent validation was crucial. Alabi described it as a meaningful benchmark: the technology had moved beyond the laboratory dish and proven itself in a living system, reproduced by researchers on a different continent under entirely different conditions.
Meanwhile, Azmain Alamgir, a postdoctoral researcher at MIT and lead author of the new paper published in the Proceedings of the National Academy of Sciences, was testing the same approach with commercial antibodies designed to target NF-kB, a driver of lung inflammation. In a mouse model of acute lung injury, the cloaked antibodies delivered via lipid nanoparticles showed therapeutic benefit. Two different diseases. Two different tissues. Two different targets. The same delivery system worked for both.
What makes this moment significant is not just the technical achievement, though that is real. It is the door it opens. Therapeutic antibodies have transformed medicine—several are already FDA-approved for cancer, autoimmune disease, and other conditions. But nearly all of them work on extracellular targets, the low-hanging fruit. The intracellular targets, where many of the most compelling disease mechanisms actually live, have remained out of reach. This technology changes that equation. For the first time, clinically validated antibodies can be directed at disease drivers inside the cell, where they can have their greatest impact.
Alabi and his colleagues have already launched a company, Cloak Bio, to pursue additional therapeutic applications. The team is also exploring whether other chemical groups beyond sulfonates might offer cloaking capabilities, potentially broadening the platform further. The researchers say they are eager to see what others will do with this material. In the language of translational science, that is the sound of a platform technology beginning to move toward the clinic.
Notable Quotes
For the first time, we can take clinically validated antibodies and deliver them to targets that are in the cell, where many of the most compelling disease drives actually reside.— Chris Alabi, Cornell professor of chemical engineering
It was satisfying to see that someone else in a completely different country under completely different conditions could take our material, apply it the way we had reported and get a positive outcome.— Chris Alabi, on independent validation by Israeli researchers
Want the full story?
Read the original at Technology Org ↗
Health & Medicine